期刊
NATURE REVIEWS CANCER
卷 17, 期 1, 页码 20-37出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/nrc.2016.108
关键词
-
类别
资金
- US National Institutes of Health (NIH) [CA151884, EB015419, R00CA160350, CA200900]
- US Department of Defense (DoD) Prostate Cancer Research Program (PCRP) Synergistic Idea Development Award [W81XWH-15-1-0728]
- David Koch-Prostate Cancer Foundation (PCF) Award in Nanotherapeutics
- Movember-PCF Challenge Award
- PCF Young Investigator Award
- National Research Foundation of Korea [K1A1A2048701]
- NATIONAL CANCER INSTITUTE [R00CA160350, U54CA151884, R01CA200900, P30CA008748] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB015419] Funding Source: NIH RePORTER
The intrinsic limits of conventional cancer therapies prompted the development and application of various nanotechnologies for more effective and safer cancer treatment, herein referred to as cancer nanomedicine. Considerable technological success has been achieved in this field, but the main obstacles to nanomedicine becoming a new paradigm in cancer therapy stem from the complexities and heterogeneity of tumour biology, an incomplete understanding of nano bio interactions and the challenges regarding chemistry, manufacturing and controls required for clinical translation and commercialization. This Review highlights the progress, challenges and opportunities in cancer nanomedicine and discusses novel engineering approaches that capitalize on our growing understanding of tumour biology and nano bio interactions to develop more effective nanotherapeutics for cancer patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据